• Je něco špatně v tomto záznamu ?

Statiny a chirurgická revaskularizace - jaký je prospěch?
[Statin use and neurologic morbidity after coronary artery bypass grafting]

Koenig MA, et al.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10013568

Statin use before surgery has been associated with reduced morbidity and mortality after vascular surgery. The effect of preoperative statin use on stroke and encephalopathy after coronary artery bypass grafting (CABG) is unclear. METHODS: A post hoc analysis was undertaken of a prospectively collected cohort of isolated CABG patients over a 10-year period at a single institution. Primary outcomes were stroke and encephalopathy. Univariable analyses identified risk factors for statin use, which were applied to a propensity score model using logistic regression and patients were divided into quintiles of propensity for statin use. Controlling for propensity score quintile, the odds ratio (OR) of combined stroke and encephalopathy (primary endpoint), cardiovascular mortality, myocardial infarction, and length of stay were compared between statin users and nonusers. RESULTS: There were 5,121 CABG patients, of whom 2,788 (54%) were taking statin medications preoperatively. Stroke occurred in 166 (3.2%) and encephalopathy in 438 (8.6%), contributing to 604 patients (11.8%) who met the primary endpoint. The unadjusted OR of stroke/encephalopathy in statin users was 1.053 (95% confidence interval [CI] 0.888-1.248, p = 0.582). Adjustment based on propensity score resulted in balance of stroke risk factors among quintiles. The propensity score-adjusted OR of stroke/encephalopathy in statin users was 0.958 (95% CI 0.784-1.170, p = 0.674). There were no significant differences in cardiovascular mortality, myocardial infarction, or length of stay between statin users and otherwise similar nonusers. CONCLUSIONS: In this large data cohort study, preoperative statin use was not associated with a decreased incidence of stroke and encephalopathy after coronary artery bypass grafting.

Statin use and neurologic morbidity after coronary artery bypass grafting

000      
00000naa 2200000 a 4500
001      
bmc10013568
003      
CZ-PrNML
005      
20111210175338.0
008      
100607s2010 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Koenig, M. A.
245    10
$a Statiny a chirurgická revaskularizace - jaký je prospěch? / $c Koenig MA, et al.
246    11
$a Statin use and neurologic morbidity after coronary artery bypass grafting
314    __
$a Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore mkoenin1@jhmi.edu
520    9_
$a Statin use before surgery has been associated with reduced morbidity and mortality after vascular surgery. The effect of preoperative statin use on stroke and encephalopathy after coronary artery bypass grafting (CABG) is unclear. METHODS: A post hoc analysis was undertaken of a prospectively collected cohort of isolated CABG patients over a 10-year period at a single institution. Primary outcomes were stroke and encephalopathy. Univariable analyses identified risk factors for statin use, which were applied to a propensity score model using logistic regression and patients were divided into quintiles of propensity for statin use. Controlling for propensity score quintile, the odds ratio (OR) of combined stroke and encephalopathy (primary endpoint), cardiovascular mortality, myocardial infarction, and length of stay were compared between statin users and nonusers. RESULTS: There were 5,121 CABG patients, of whom 2,788 (54%) were taking statin medications preoperatively. Stroke occurred in 166 (3.2%) and encephalopathy in 438 (8.6%), contributing to 604 patients (11.8%) who met the primary endpoint. The unadjusted OR of stroke/encephalopathy in statin users was 1.053 (95% confidence interval [CI] 0.888-1.248, p = 0.582). Adjustment based on propensity score resulted in balance of stroke risk factors among quintiles. The propensity score-adjusted OR of stroke/encephalopathy in statin users was 0.958 (95% CI 0.784-1.170, p = 0.674). There were no significant differences in cardiovascular mortality, myocardial infarction, or length of stay between statin users and otherwise similar nonusers. CONCLUSIONS: In this large data cohort study, preoperative statin use was not associated with a decreased incidence of stroke and encephalopathy after coronary artery bypass grafting.
650    _2
$a financování organizované $7 D005381
650    _2
$a senioři $7 D000368
650    _2
$a nemoci mozku $x epidemiologie $x etiologie $x prevence a kontrola $7 D001927
650    _2
$a kohortové studie $7 D015331
650    _2
$a koronární bypass $x škodlivé účinky $7 D001026
650    _2
$a databáze faktografické $7 D016208
650    _2
$a inhibitory enzymů $x terapeutické užití $7 D004791
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a předoperační péče $7 D011300
650    _2
$a prospektivní studie $7 D011446
650    _2
$a cévní mozková příhoda $x epidemiologie $x etiologie $x prevence a kontrola $7 D020521
650    _2
$a neúspěšná terapie $7 D017211
650    _2
$a Propensity Score
773    0_
$w MED00012706 $t Clinical cardiology alert $g Roč. 4, č. 2 (2010), s. 10-11 $x 1213-2586
787    18
$w bmc10013570 $i Recenze v: $t Komentář [k článku Statiny a chirurgická revaskularizace - jaký je prospěch?]
910    __
$a ABA008 $b B 2242 $c 407 a $y 8
990    __
$a 20100607122824 $b ABA008
991    __
$a 20100901101745 $b ABA008
999    __
$a ok $b bmc $g 749431 $s 613078
BAS    __
$a 3
BMC    __
$a 2010 $b 4 $c 2 $d 10-11 $m Clinical Cardiology Alert $x MED00012706
LZP    __
$a 2010-15/mkme

Najít záznam